EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Inhibition of CDK1 by RO-3306 Exhibits Anti-Tumorigenic Effects in Ovarian Cancer Cells and a Transgenic Mouse Model of Ovarian Cancer

Yu Huang iD, Yali Fan, Ziyi Zhao, Xin Zhang, Katherine Tucker, Allison Staley, Hongyan Suo, Wenchuan Sun, Xiaochang Shen, Boer Deng iD, Stuart R Pierce, Lindsay West und 4 weitere

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms241512375 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Yu Huang und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecologic Oncology, Chongqing University Cancer Hospital, Chongqing 400044, China. Hauptthemen laut MEDLINE: CDC2 Protein Kinase, Ovarian Neoplasms. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, NCI NIH HHS, UNC University Cancer Research Fund (UCRF).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ovarian cancer is the deadliest gynecological malignancy of the reproductive organs in the United States. Cyclin-dependent kinase 1 (CDK1) is an important cell cycle regulatory protein that specifically controls the G2/M phase transition of the cell cycle. RO-3306 is a selective, ATP-competitive, and cell-permeable CDK1 inhibitor that shows potent anti-tumor activity in multiple pre-clinical models. In this study, we investigated the effect of CDK1 expression on the prognosis of patients with ovarian cancer and the anti-tumorigenic effect of RO-3306 in both ovarian cancer cell lines and a genetically engineered mouse model of high-grade serous ovarian cancer (KpB model). In 147 patients with epithelial ovarian cancer, the overexpression of CDK1 was significantly associated with poor prognosis compared with a low expression group. RO-3306 significantly inhibited cellular proliferation, induced apoptosis, caused cellular stress, and reduced cell migration. The treatment of KpB mice with RO-3306 for four weeks showed a significant decrease in tumor weight under obese and lean conditions without obvious side effects. Overall, our results demonstrate that the inhibition of CDK1 activity by RO-3306 effectively reduces cell proliferation and tumor growth, providing biological evidence for future clinical trials of CDK1 inhibitors in ovarian cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CDC2 Protein KinaseOvarian NeoplasmsHumansFemaleMiceAnimalsMice, TransgenicCell Line, TumorCell ProliferationCarcinogenesisQuinolinesThiazoles

Stichwörter der Autor:innen

CDK1RO-3306apoptosisinvasionovarian cancer

Substanzen

CDC2 Protein KinaseRO 3306QuinolinesThiazolesCDK1 protein, human

Autor:innen und Institutionen

  • Department of Gynecologic Oncology, Chongqing University Cancer Hospital, Chongqing 400044, China.
  • Division of Gynecologic Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
  • Department of Gynecologic Oncology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing Maternal and Child Health Care Hospital, Beijing 100054, China.
  • Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
  • Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.

ORCID-Profile: Yu Huang, Boer Deng

Förderung

  • NIGMS NIH HHS
  • NCI NIH HHS
  • UNC University Cancer Research Fund (UCRF)
  • National Institutes of Health
  • America Cancer Society

Zitieren

APA

Huang, Y., Fan, Y., Zhao, Z., Zhang, X., Tucker, K., Staley, A., Suo, H., Sun, W., Shen, X., Deng, B., Pierce, S. R., West, L., Yin, Y., Emanuele, M. J., Zhou, C., & Bae-Jump, V. (2023). Inhibition of CDK1 by RO-3306 Exhibits Anti-Tumorigenic Effects in Ovarian Cancer Cells and a Transgenic Mouse Model of Ovarian Cancer. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms241512375

Vancouver

Huang Y, Fan Y, Zhao Z, Zhang X, Tucker K, Staley A, et al. Inhibition of CDK1 by RO-3306 Exhibits Anti-Tumorigenic Effects in Ovarian Cancer Cells and a Transgenic Mouse Model of Ovarian Cancer. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms241512375

BibTeX
@article{Huang2023,
  author = {Huang, Yu and Fan, Yali and Zhao, Ziyi and Zhang, Xin and Tucker, Katherine and Staley, Allison and Suo, Hongyan and Sun, Wenchuan and Shen, Xiaochang and Deng, Boer and Pierce, Stuart R and West, Lindsay and Yin, Yajie and Emanuele, Michael J and Zhou, Chunxiao and Bae-Jump, Victoria},
  title = {Inhibition of CDK1 by RO-3306 Exhibits Anti-Tumorigenic Effects in Ovarian Cancer Cells and a Transgenic Mouse Model of Ovarian Cancer},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms241512375}
}
Kostenlos starten →